InterMune Reports Third Quarter 2009 Financial Results and Business ...(nd 900mg q12h) and three-times-daily reg...),Health

Leadership Additions - Preparation for Potential Pirfenidone Launch

The company today announced in a separate press release the expansion of its senior leadership team that will prepare the company to bring pirfenidone to patients, should InterMune's NDA and/or MAA be granted approval by the regulatory authorities in the United States and Europe, respectively:

• Sr. Vice President and General Manager, Europe - Mr. Giacomo di Nepi.
• Vice President, Sales - Ms. Terri Shoemaker.
• Vice President, Marketing - Mr. Erik Harris.
• Vice President, Managed Care and Access - Mr. Darren Cline.
  

Further expansion of InterMune's commercial infrastructure will be made upon the successful outcome of key regulatory events related to the NDA and MAA, expected in 2010.

2009 Key Project Guidance

The company provided the following guidance on its key development projects, pirfenidone and ITMN-191 (RG7227).

    Milestones And Key Events                                  Expected Date
    -------------------------                                  ------------
'/>"/>
SOURCE  InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 
Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3